TEMENOS
6.9.2022 11:56:34 CEST | Business Wire | Press release
Temenos (SIX: TEMN) today announced that it has been recognized as a leader in The Forrester Wave™: Digital Banking Processing Platforms for Corporate Banking, Q3 2022. Temenos believes that its position as a leader reflects the advances in Temenos open platform for composable banking and the broad set of banking services that cover all areas of corporate banking. According to the Forrester report, “Temenos sets the pace in AI-powered banking capabilities and application architecture”. Temenos was also named a Leader in The Forrester Wave™: Digital Banking Processing Platforms for Retail Banking, Q3 2022 evaluation.
The corporate banking report, authored by Jost Hoppermann, Vice President and Principal Analyst, Forrester, notes: “The vendor’s [Temenos’] strategy shows no weak spots. […] The [Temenos] product roadmap includes the continuation of an overarching corporate banking rejuvenation program, AI-powered operations, and fine-grain banking services out of the cloud that are aligned with the concept of a lean core.” The report also states, “Its reference customers reported that the system is very modular, could satisfy almost any needs or requirements, and allows a bank to differentiate.”
This Forrester Wave™ evaluates the top 7 corporate banking platform vendors against 33 criteria, according to their current offering, strategy and market presence. Temenos received the highest score in the strategy category and the 2nd highest score in the current offering category, which Temenos believes reflects its success in serving clients of all tiers to deliver corporate banking services such as Commerce Bank, Bank of Queensland, and Shanghai Commercial & Savings Bank (SCSB).
Max Chuard, Chief Executive Officer, Temenos, said: “We are proud to be recognized as a leader in the Forrester Wave report for corporate banking. Banks have a renewed focus on corporate growth and are seeking more agile, progressive renovation, targeting quicker gains at lower risk and cost – enabled by SaaS, microservices, and packaged banking capabilities. We believe this recognition as a leader by Forrester shows the maturity of our open platform for composable banking and market adoption. Helping clients of all sizes to reduce total cost of ownership, deliver higher service levels with reduced turnaround times and capture new revenue opportunities.”
According to the Forrester report on corporate banking: “Examples of the [Temenos] DBPP’s broad and rich capabilities include functionally rich AI-powered banking capabilities with a strong focus on explainable AI and a state-of-the-art application architecture that has been designed from the ground up to offer choice to banks.”
Temenos was also recently named a ‘Global Power Seller’ and ‘Top Global Player’ based on Forrester’s Global Banking Platform Deals Survey 2022 in the report, ‘Identify The Winners In A Consolidating Banking Platform Market To Make Informed Transformation Decisions.’
With Temenos’ open platform, clients can compose solutions based on granular banking capabilities across all areas of corporate banking including corporate lending, trade finance, payments and cash and liquidity management, with the addition of embedded analytics and compliance. It offers pre-composed, front-to-back solutions and clients and partners can create customized banking services themselves using a personalized sandbox. All these can be integrated with third-party solutions on Temenos Exchange, an ecosystem of pre-integrated fintech solutions. The platform is cloud-native and cloud-agnostic, offering the flexibility to run on-premise, on any private or public cloud, or as SaaS through the Temenos Banking Cloud.
– Ends –
About Temenos
Temenos (SIX: TEMN) is the world’s leading open platform for composable banking, creating opportunities for over 1.2 billion people around the world every day. We serve over 3000 banks from the largest to challengers and community banks in 150+ countries by helping them build new banking services and state-of-the-art customer experiences. The Temenos open platform helps our top-performing clients achieve return on equity three times the industry average and cost-to-income ratios half the industry average.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005567/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
